Assessing the effectiveness and safety of a chikungunya vaccine in at-risk populations
Official title: Real-world Effectiveness, Safety, and Immunogenicity of Chikungunya Vaccination During an Epidemic Period: an Ambispective Study in Réunion Island and French Guiana.
Run by Centre Hospitalier Universitaire de la Réunion · NCT06928753 · Data updated 2026-11-12
This study is testing a chikungunya vaccine to see if it helps protect seniors and people with other health issues during an outbreak.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1505 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de la Réunion Academic / other |
| Locations | 2 sites (Cayenne and 1 other locations) |
| Status | Recruiting |
| Started | April 18, 2025 |
| Main results expected | June 2027 |
| Study ends | December 2027 |
| Registry record updated | September 28, 2026 |
| Trial ID | NCT06928753 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study include seniors and individuals with comorbid conditions who are eligible for anti-chikungunya vaccination as defined by the French Health Authority.
✕Probably not a fit
Patients who are pregnant, have contraindications to vaccination, or have received immunoglobulin or blood products within the last three months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective study evaluates the real-world efficacy, safety, and immunogenicity of the IXCHIQ® vaccine in vulnerable individuals, such as seniors and patients with comorbidities, during a chikungunya epidemic in La Réunion. The study aims to gather data that will inform a larger cluster randomized trial on a population scale. Participants will be monitored for adverse effects and immune response to the vaccine, contributing to the understanding of its effectiveness in preventing severe forms of chikungunya virus infection.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the effectiveness of the chikungunya vaccine, potentially reducing the incidence of severe disease in at-risk populations.
How similar studies have gone: While this study focuses on a specific population and context, similar studies on vaccine effectiveness in at-risk groups have shown promising results, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Retrospective study VIMKUNYA or IXCHIQ * Adult (Aged 18 or above) * Adult (Aged 18 or above) eligible for anti-chikungunya vaccination according to French High Health Authority (HAS) Prospective study * VIMKUNYA: Adult (Aged 18 or above) eligible for anti-chikungunya vaccination according to French High Health Authority (HAS) * IXCHIQ: Adult (Aged 18 -64) eligible for anti-chikungunya vaccination according to French High Health Authority (HAS) Eligibility Criteria common to both groups * Agreeing to participate in study * Beneficiary of French social security coverage * Signature of informed consent form Exclusion Criteria: * Pregnant or breastfeeding women entering the prospective study * Vaccine (IXCHIQ or VIMKUNYA) contraindication for patients undergoing medical treatment * Persons under guardianship, curatorship or safeguard of justice * Anyone who has received immunoglobulin or a blood or plasma transfusion 3 months prior to vaccine administration * Missing French Social security coverage
Where it's running
-
Centre Hospitalier Universitaire de Guyane
Cayenne, French Guiana Recruiting -
Centre Hospitalier Universitaire de La Réunion
Saint-Denis, Reunion Active not recruiting
Study contacts
- Study coordinator: Patrick GERARDIN, MD
- Email: patrick.gerardin@chu-reunion.fr
- Phone: (262) 2 62 35 9435
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Plasma transfusion to protect newborns exposed to chikungunya from brain inflammation
This trial will test whether giving plasma from a recent chikungunya-infected donor to newborns whose mothers had chikungunya around delivery helps prevent encephalitis or encephalopathy in the first five days of life.
-
Testing safety and immune response of an inactivated chikungunya vaccine in people aged 12–65
This trial will test whether two doses of the BBV87 inactivated chikungunya vaccine are safe and produce protective immune responses in healthy people aged 12–65.
-
Chikungunya Vaccine Test in Teens and Adults to See If It Prevents Illness
A vaccine made from chikungunya virus-like particles is being tested in adolescents and adults to see if it prevents chikungunya disease and how safe and immune-boosting it is.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.